Andrew S. Ittleman/LinkedIn
Nov 5, 2025, 05:27
Andrew S. Ittleman: Florida’s New Stem Cell Laws Raise FDA and Patient Safety Concerns
Andrew S. Ittleman, Owner at Fuerst Ittleman David & Joseph, shared on LinkedIn:
”In July, Florida passed new “stem cell therapy” laws, which allow physicians to administer allogeneic “stem cell” products to patients. Among other problems with Florida’s new stem cell laws, they (i) authorize products which FDA prohibits, (ii) do not define “stem cell,” (iii) create a risk of patient confusion.
We have decades of history to understand the potential consequences of these laws, but that history seems to have been ignored during the legislative process. I explore these issues in the article available at the link below.”
Find more information here.
Stay informed with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia